As Merck & Co., Bristol Myers Squibb and Pfizer have hopped on the PD-(L)1xVEGF bispecific bandwagon, the question becomes ...

In 1992, graduate student Yasumasa Ishida discovered PD-1, marking the beginning of a journey that would make this molecule a ...

New phase 3 data show that sacituzumab govitecan plus pembrolizumab delays cancer progression in PD-L1-positive metastatic ...

More information: Wyatt Wofford et al, Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response, Cell Reports (2024).

Reference: Wofford W, Kim J, Kim D, et al. Alterations of ceramide synthesis induce PD-L1 internalization and signaling to regulate tumor metastasis and immunotherapy response. Cell Reports. 2024;43(8 ...

Petosemtamab acts by inhibiting EGFR signaling, binding LGR5 for EGFR internalization ... with pembrolizumab as 1L treatment of PD-L1+ recurrent/metastatic (r/m) head and neck squamous cell ...

The checkpoint inhibitor pembrolizumab has been approved for recurrent TNBC for patients with at least 10% of their tumor cells expressing the immunosuppressive protein PD-L1. PD-L1 on the surface ...

Dublin, March 03, 2025 (GLOBE NEWSWIRE) -- The "PD-1 x VEGF and PD-L1 x VEGF Bispecific Antibodies: A Business, Pipeline And Competitor Analysis From An Industry Perspective" report has been added ...

"With APVO711, we're advancing an innovative dual-mechanism approach to immunotherapy-one that not only boosts the immune system through PD-L1 blockade but also facilitates T-cell priming via CD40 ...